Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Kronos Bio (NASDAQ: KRON) presented preclinical data for its p300 KAT inhibitor program at ACR Convergence 2024. The research focused on KB-7898, demonstrating its ability to reduce inflammation through multiple pathways. Key findings showed that KB-7898 modulated proinflammatory signaling and reduced production of disease-related inflammation markers, including IgG, IL-23, and IL-17A. In the Keyhole Limpet Hemocyanin booster, it achieved up to 50% reduction in KLH-IgG production. The compound also significantly decreased inflammation in a collagen-induced arthritis rat model. The company is currently exploring strategic alternatives, including potential partnerships for its p300 KAT inhibitor programs.
Kronos Bio (NASDAQ: KRON) ha presentato dati preclinici per il suo programma di inibitori p300 KAT durante l'ACR Convergence 2024. La ricerca si è concentrata su KB-7898, dimostrando la sua capacità di ridurre l'infiammazione attraverso molteplici vie. I risultati chiave hanno mostrato che KB-7898 ha modulato il segnale proinfiammatorio e ridotto la produzione di marcatori di infiammazione correlati alla malattia, tra cui IgG, IL-23 e IL-17A. Nel potenziatore Keyhole Limpet Hemocyanin, ha raggiunto fino a un 50% di riduzione nella produzione di KLH-IgG. Il composto ha anche diminuito significativamente l'infiammazione in un modello di artrite indotta da collagene nei ratti. Attualmente, l'azienda sta esplorando alternative strategiche, comprese potenziali partnership per i suoi programmi di inibitori p300 KAT.
Kronos Bio (NASDAQ: KRON) presentó datos preclínicos para su programa de inhibidores de p300 KAT en ACR Convergence 2024. La investigación se centró en KB-7898, demostrando su capacidad para reducir la inflamación a través de múltiples vías. Los hallazgos clave mostraron que KB-7898 moduló la señalización proinflamatoria y redujo la producción de marcadores de inflamación relacionados con la enfermedad, incluyendo IgG, IL-23 e IL-17A. En el potenciador de Keyhole Limpet Hemocyanin, logró hasta un 50% de reducción en la producción de KLH-IgG. El compuesto también disminuyó significativamente la inflamación en un modelo de artritis inducida por colágeno en ratas. La compañía está explorando actualmente alternativas estratégicas, incluyendo posibles asociaciones para sus programas de inhibidores de p300 KAT.
Kronos Bio (NASDAQ: KRON)는 ACR Convergence 2024에서 p300 KAT 인히비터 프로그램에 대한 전임상 데이터를 발표했습니다. 연구는 KB-7898에 초점을 맞추었으며, 여러 경로를 통해 염증을 줄이는 능력을 보여주었습니다. 주요 발견에서는 KB-7898이 프로염증 신호를 조절하고 IgG, IL-23, IL-17A와 같은 질병 관련 염증 마커의 생산을 줄였다는 것을 보여주었습니다. Keyhole Limpet Hemocyanin 부스터에서는 KLH-IgG 생산에서 최대 50% 감소를 달성했습니다. 이 화합물은 또한 콜라겐 유도 관절염 쥐 모델에서 염증을 유의미하게 감소시켰습니다. 현재 이 회사는 p300 KAT 인히비터 프로그램에 대한 잠재적 파트너십을 포함한 전략적 대안을 탐색하고 있습니다.
Kronos Bio (NASDAQ: KRON) a présenté des données précliniques pour son programme d'inhibiteurs p300 KAT lors de l'ACR Convergence 2024. La recherche s'est concentrée sur KB-7898, démontrant sa capacité à réduire l'inflammation par plusieurs voies. Les résultats clés ont montré que KB-7898 modulait la signalisation pro-inflammatoire et réduisait la production de marqueurs d'inflammation liés à la maladie, notamment IgG, IL-23 et IL-17A. Dans le booster Keyhole Limpet Hemocyanin, il a atteint jusqu'à 50% de réduction de la production de KLH-IgG. Le composé a également significativement diminué l'inflammation dans un modèle de rats souffrant d'arthrite induite par le collagène. L'entreprise est actuellement en train d'explorer des alternatives stratégiques, y compris des partenariats potentiels pour ses programmes d'inhibiteurs p300 KAT.
Kronos Bio (NASDAQ: KRON) stellte auf der ACR Convergence 2024 präklinische Daten zu seinem p300 KAT-Inhibitor-Programm vor. Die Forschung konzentrierte sich auf KB-7898, das seine Fähigkeit zur Reduzierung von Entzündungen über mehrere Wege nachwies. Wichtige Ergebnisse zeigten, dass KB-7898 die proinflammatorische Signalübertragung modulierte und die Produktion von krankheitsbezogenen Entzündungsmarkern wie IgG, IL-23 und IL-17A verringerte. Im Keyhole Limpet Hemocyanin-Booster erreichte es eine 50%ige Reduktion der KLH-IgG-Produktion. Die Verbindung verringerte auch signifikant die Entzündung in einem Kollagen-induzierten Arthritis-Rattenmodell. Das Unternehmen prüft derzeit strategische Alternativen, einschließlich potenzieller Partnerschaften für seine p300 KAT-Inhibitor-Programme.
- Preclinical data showed significant anti-inflammatory effects in multiple pathways
- Achieved up to 50% reduction in KLH-IgG production
- Demonstrated positive results in rheumatoid arthritis rat model
- Two programs approaching important development milestones: KB-9558 (IND-ready by end of 2024) and KB-7898 (in IND-enabling studies)
- Company seeking strategic alternatives, suggesting possible financial or strategic challenges
- Programs still in preclinical stage, indicating long path to commercialization
Insights
The preclinical data for Kronos Bio's p300 KAT inhibitor program shows promising results in reducing inflammation through multiple mechanisms. The key findings demonstrate up to
However, this news should be viewed cautiously in the context of the company's November 13 announcement about exploring strategic alternatives. While the data is scientifically interesting, the company's search for strategic options, including potential partnering of these programs, suggests uncertainty about their independent development capability. The transition from preclinical to clinical phases requires substantial resources and the company's strategic review indicates potential financial or operational constraints.
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today highlighted preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology's annual meeting, ACR Convergence 2024. The oral presentation will take place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST.
Kronos Bio has been exploring the utility of KB-7898, a p300 KAT inhibitor, for autoimmune indications given the role of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells and other immune cells. The data demonstrates the ability of p300 KAT inhibition to modulate the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases.
In the presentation titled, "p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines", the presenter, Dr. Peter Rahl, Vice President, Discovery Biology at Kronos, will summarize the experiments that led to the following key findings:
- In ex vivo primary cell models, the authors demonstrated that p300 KAT inhibition by KB-7898 modulated proinflammatory signaling and blunted the production of multiple clinically validated molecules that drive disease-related inflammation, including secreted IgG, IL-23, and IL-17A
- p300 KAT inhibition by KB-7898 led to dose-dependent reduction up to
50% of KLH-IgG production in the Keyhole Limpet Hemocyanin booster - In a collagen-induced arthritis (CIA) rat model, one of the most commonly used models for studying rheumatoid arthritis, p300 inhibition significantly decreased inflammation, as measured by joint swelling, clinical score and histopathology.
The presentation is now available under the Science & Pipeline section of the Kronos Bio website on November 14, 2024. The abstract can be found on the American College of Rheumatology’s website.
As announced on November 13, 2024, Kronos Bio is exploring strategic alternatives for the Company and its remaining internally developed preclinical assets. One potential scenario could include partnering the two p300 lysine acetyltransferase (KAT) inhibitor programs: an oncology candidate, KB-9558, for multiple myeloma and HPV-driven cancers expected to be IND-ready by the end of 2024, and an autoimmune disease candidate, KB-7898, for Sjogren’s disease which has begun IND-enabling studies.
About Kronos Bio
Kronos Bio is a biopharmaceutical company developing small molecule therapeutics that address deregulated transcription, a hallmark of cancer and autoimmune diseases. Our proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors. We screen for and optimize small molecules that target these cofactors in a disease-specific context.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com or follow the Company on LinkedIn.
FAQ
What were the key findings of Kronos Bio's (KRON) p300 KAT inhibitor study presented at ACR 2024?
What are the development stages of Kronos Bio's (KRON) two p300 KAT inhibitor programs?
Why is Kronos Bio (KRON) exploring strategic alternatives in November 2024?
